story of the week
Salvage Ipilimumab and Nivolumab in Patients With mRCC After Prior Immune Checkpoint Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
J. Clin. Oncol 2020 Jun 03;[EPub Ahead of Print], A Gul, TF Stewart, CM Mantia, NJ Shah, ES Gatof, Y Long, KD Allman, MC Ornstein, HJ Hammers, DF McDermott, MB Atkins, M Hurwitz, BI RiniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.